While these results support the integration of SYK and BTK inhibitors into the treatment paradigm for adult ITP—particularly in patients with inadequate responses or intolerance to conventional therapies—further high-quality, long-term RCTs are warranted to confirm these findings, assess sustained efficacy, and determine their comparative effectiveness against existing standard-of-care options. The gene discussed is BTK; the disease is autoimmune thrombocytopenic purpura.